Alumis (ALMS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$7.4M

Revenue (quarter)

$1.7M

Revenue growth (year over year)

−37.66%

Gross profit (trailing twelve months)

$7.4M

Gross margin

100.00%

Net income (trailing twelve months)

−$439.0M

Net income (quarter)

−$142.2M

Net income growth (year over year)

−339.75%

Net margin

−5933.45%

Return on equity

−93.65%

EPS (trailing twelve months)

−$4.11

Book value per share

$3.52

P/E (trailing twelve months)

—

Price to book

1.81

Debt to assets

19.35%

Payout ratio

—

Dividend yield

—

Company profile

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

• Is Alumis (ALMS) profitable?

  No. Alumis reported a net loss of $439.0M over the trailing twelve months.

• How much revenue does Alumis (ALMS) make?

  Alumis generated $7.4M in revenue over the trailing twelve months, down 37.66% year over year.

• How do I buy stock in Alumis (ALMS)?

  ALMS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.